MX2017013562A - Reguladores de microbioma y usos relacionados de los mismos. - Google Patents
Reguladores de microbioma y usos relacionados de los mismos.Info
- Publication number
- MX2017013562A MX2017013562A MX2017013562A MX2017013562A MX2017013562A MX 2017013562 A MX2017013562 A MX 2017013562A MX 2017013562 A MX2017013562 A MX 2017013562A MX 2017013562 A MX2017013562 A MX 2017013562A MX 2017013562 A MX2017013562 A MX 2017013562A
- Authority
- MX
- Mexico
- Prior art keywords
- related uses
- microbiome regulators
- microbiome
- regulators
- disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/733—Fructosans, e.g. inulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
- C12Q1/10—Enterobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
- A61K2035/115—Probiotics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
La presente invención se refiere a composiciones que comprenden reguladores de microbioma, así como métodos de uso de los mismos para la modulación de la microbiota humana y para tratar o prevenir enfermedad, trastornos o afecciones relacionados.
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562152007P | 2015-04-23 | 2015-04-23 | |
US201562152017P | 2015-04-23 | 2015-04-23 | |
US201562152016P | 2015-04-23 | 2015-04-23 | |
US201562152005P | 2015-04-23 | 2015-04-23 | |
US201562152011P | 2015-04-23 | 2015-04-23 | |
US201562255366P | 2015-11-13 | 2015-11-13 | |
US201562255365P | 2015-11-13 | 2015-11-13 | |
PCT/US2016/029083 WO2016172658A2 (en) | 2015-04-23 | 2016-04-23 | Microbiome regulators and related uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017013562A true MX2017013562A (es) | 2018-05-28 |
Family
ID=56027154
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017013562A MX2017013562A (es) | 2015-04-23 | 2016-04-23 | Reguladores de microbioma y usos relacionados de los mismos. |
Country Status (10)
Country | Link |
---|---|
US (3) | US20180296582A1 (es) |
EP (1) | EP3285778A2 (es) |
JP (1) | JP2018513196A (es) |
CN (1) | CN107708704A (es) |
AU (1) | AU2016253011A1 (es) |
CA (1) | CA2983016A1 (es) |
MX (1) | MX2017013562A (es) |
RU (1) | RU2017134547A (es) |
SG (1) | SG11201708635QA (es) |
WO (1) | WO2016172658A2 (es) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11419903B2 (en) | 2015-11-30 | 2022-08-23 | Seed Health, Inc. | Method and system for reducing the likelihood of osteoporosis |
US11951139B2 (en) | 2015-11-30 | 2024-04-09 | Seed Health, Inc. | Method and system for reducing the likelihood of osteoporosis |
US11273187B2 (en) | 2015-11-30 | 2022-03-15 | Joseph E. Kovarik | Method and system for reducing the likelihood of developing depression in an individual |
US11844720B2 (en) | 2011-02-04 | 2023-12-19 | Seed Health, Inc. | Method and system to reduce the likelihood of dental caries and halitosis |
US11951140B2 (en) | 2011-02-04 | 2024-04-09 | Seed Health, Inc. | Modulation of an individual's gut microbiome to address osteoporosis and bone disease |
US10842834B2 (en) | 2016-01-06 | 2020-11-24 | Joseph E. Kovarik | Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease |
US10512661B2 (en) | 2011-02-04 | 2019-12-24 | Joseph E. Kovarik | Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease |
US11833177B2 (en) | 2013-12-20 | 2023-12-05 | Seed Health, Inc. | Probiotic to enhance an individual's skin microbiome |
US11826388B2 (en) | 2013-12-20 | 2023-11-28 | Seed Health, Inc. | Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation |
US11839632B2 (en) | 2013-12-20 | 2023-12-12 | Seed Health, Inc. | Topical application of CRISPR-modified bacteria to treat acne vulgaris |
WO2016007762A1 (en) | 2014-07-09 | 2016-01-14 | Duke University | Compositions and methods for the repair of myelin |
CA2954662C (en) | 2014-07-09 | 2024-03-19 | Midori Usa, Inc. | Oligosaccharide compositions and methods for producing thereof |
ES2755042T3 (es) | 2015-01-26 | 2020-04-21 | Cadena Bio Inc | Composiciones de oligosacáridos para el uso como alimento para animales y sus métodos para producirlas |
PT3071235T (pt) | 2015-01-26 | 2018-02-21 | Kaleido Biosciences Inc | Produtos terapêuticos de glicanos e respetivos métodos relacionados |
WO2016172657A2 (en) | 2015-04-23 | 2016-10-27 | Kaleido Biosciences, Inc. | Glycan therapeutics and methods of treatment |
US10945974B2 (en) | 2015-06-01 | 2021-03-16 | Xeno Biosciences Inc. | Methods and compositions to modulate the gut microbiota and to manage weight |
US20210137964A1 (en) | 2016-07-13 | 2021-05-13 | Kaleido Biosciences, Inc. | Glycan compositions and methods of use |
TWI673056B (zh) * | 2016-07-22 | 2019-10-01 | 大江生醫股份有限公司 | 包含細菌的水凝膠及其製備方法 |
WO2018045493A1 (zh) * | 2016-09-06 | 2018-03-15 | 深圳华大基因研究院 | 克里斯坦森氏菌(Christensenella intestinihominis)及其应用 |
IL308091A (en) | 2016-09-13 | 2023-12-01 | Allergan Inc | Stabilized Clostridium toxin preparations without protein |
AU2017368074A1 (en) | 2016-11-30 | 2019-06-13 | Xeno Biosciences Inc. | Pharmaceutical preparations and methods to manage weight and to modulate the gut microbiota |
AU2017370682A1 (en) | 2016-12-06 | 2019-06-20 | Kaleido Biosciences, Inc. | Glycan polymers and related methods thereof |
WO2018132676A1 (en) * | 2017-01-13 | 2018-07-19 | Duke University | Compositions and methods for the treatment of myelin related and inflammation related diseases or disorders |
EP3603420A4 (en) * | 2017-03-28 | 2021-04-14 | Ajinomoto Co., Inc. | FOOD TO IMPROVE THE INTRAINTESTINAL ENVIRONMENT |
EP3612570A4 (en) | 2017-04-17 | 2021-01-13 | The University of Chicago | POLYMER MATERIALS FOR DELIVERING SHORT CHAIN FATTY ACIDS TO THE INTESTINAL FOR HUMAN HEALTH APPLICATIONS AND DISEASE TREATMENT |
AR112328A1 (es) | 2017-07-05 | 2019-10-16 | Evelo Biosciences Inc | Composiciones y métodos para tratamiento de cáncer usando bifidobacterium animalis ssp. lactis |
US20210161942A1 (en) | 2017-07-13 | 2021-06-03 | Kaleido Biosciences, Inc. | Glycan compositions and methods of use |
KR102212606B1 (ko) | 2017-09-28 | 2021-02-05 | 주식회사 고바이오랩 | 짧은 사슬 지방산 생성 장내 세균 군집의 변화를 이용한 알코올성 간 질환의 진단 및 치료용 조성물 |
US11697692B2 (en) | 2017-11-03 | 2023-07-11 | Dsm Nutritional Products, Llc | Methods of producing glycan polymers |
CN111315388A (zh) | 2017-11-03 | 2020-06-19 | 卡莱多生物科技有限公司 | 聚糖制剂和用于高氨血症的使用方法 |
CN111417398A (zh) | 2017-11-03 | 2020-07-14 | 卡莱多生物科技有限公司 | 用于治疗感染的聚糖制剂 |
WO2019146082A1 (ja) * | 2018-01-26 | 2019-08-01 | 松谷化学工業株式会社 | 自閉症スペクトラム障害及び精神疾患改善剤 |
JP2021516330A (ja) * | 2018-03-16 | 2021-07-01 | プソマーゲン, インコーポレイテッドPsomagen, Inc. | バイオインフォマティクスアプローチに基づく、診断及び治療を含む、代謝関連状態の特徴解析のための方法及びシステム |
EP3808357A4 (en) * | 2018-05-31 | 2022-02-16 | BGI Shenzhen | COMPOSITION AND USES THEREOF |
EP3597202A1 (en) * | 2018-07-20 | 2020-01-22 | Maat Pharma | Fecal microbiota composition, for use in reducing treatment-induced inflammation |
US11925660B2 (en) | 2018-08-10 | 2024-03-12 | Simeon Investment, Inc. | Treatment for obesity with superabsorbent materials |
US11918602B2 (en) | 2018-08-10 | 2024-03-05 | Simeon Investment, Inc. | Methods for reducing cholesterol with superabsorbent materials |
KR20210134301A (ko) * | 2018-11-08 | 2021-11-09 | 디에스엠 아이피 어셋츠 비.브이. | 위장 대사물질을 조절하는 방법 |
MX2021005245A (es) | 2018-11-08 | 2021-06-18 | Kaleido Biosciences Inc | Composiciones de oligosacaridos y metodos de uso de las mismas. |
CN109497555A (zh) * | 2018-11-27 | 2019-03-22 | 浙江华康药业股份有限公司 | 一种槐糖微胶囊及其制备方法和应用 |
BR112021013783A2 (pt) * | 2019-01-31 | 2021-09-21 | Kimberly-Clark Worldwide, Inc. | Método para manter uma faixa de ph, e, produto |
CN113660980A (zh) * | 2019-02-07 | 2021-11-16 | 通用医疗公司 | 用于治疗或预防恶心的类胡萝卜素 |
RU2705379C1 (ru) * | 2019-06-03 | 2019-11-07 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Астраханский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Астраханский ГМУ Минздрава России) | Способ ранней диагностики язвенно-некротического энтероколита у новорожденных |
CN110172427A (zh) * | 2019-06-11 | 2019-08-27 | 江南大学 | 一种提高狄氏副拟杆菌冻干存活率的方法及应用 |
CN110106163B (zh) * | 2019-06-19 | 2021-02-19 | 西南大学 | 岩藻多糖及其水解寡糖在制备益生菌保护剂中的应用及方法 |
CN110484449B (zh) * | 2019-07-30 | 2022-09-02 | 南京农业大学 | 一种多菌灵降解菌的保护剂及其制备方法和应用 |
JP2022546117A (ja) * | 2019-08-28 | 2022-11-02 | アッセンブリー バイオサイエンシズ,インコーポレイテッド | 細菌種を含む組成物及びそれに関連する方法 |
GB201914384D0 (en) * | 2019-10-04 | 2019-11-20 | Mars Inc | Microbiome Interventions |
CN111870617B (zh) * | 2019-11-04 | 2022-06-10 | 深圳碳云智能数字生命健康管理有限公司 | 肠道益生菌补剂配方的确定方法、装置、存储介质及处理器 |
CN110916192B (zh) * | 2019-11-25 | 2021-04-13 | 垒途智能教科技术研究院江苏有限公司 | 一种具有防治儿童青少年自闭症的益生菌矿物粉及其应用 |
WO2021222660A1 (en) * | 2020-04-30 | 2021-11-04 | Kaleido Biosciences, Inc. | Oligosaccharide compositions and methods of use thereof for treating viral infections |
CA3196600A1 (en) * | 2020-09-25 | 2022-03-31 | Dsm Nutritional Products, Llc | Oligosaccharide compositions and methods of use |
JP2024510726A (ja) * | 2021-03-19 | 2024-03-11 | ディーエスエム アイピー アセッツ ビー.ブイ. | 腸内細菌叢におけるフソバクテリウム(Fusobacteria)の菌数を減少させる方法 |
TWI788840B (zh) * | 2021-05-10 | 2023-01-01 | 我的輕食有限公司 | 嗜酸乳桿菌tw01菌株及其益生菌組合物與用途 |
CN114591879B (zh) * | 2022-05-11 | 2022-12-06 | 中国农业大学 | 一种抑制幽门螺杆菌的发酵乳杆菌及其应用 |
CN117045686B (zh) * | 2023-10-08 | 2024-02-13 | 首都医科大学附属北京友谊医院 | 解纤维素拟杆菌在制备药物中的应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10147100A1 (de) * | 2001-09-25 | 2003-04-17 | Numico Res B V | Antiinfektive Kohlenhydrate |
GB0229015D0 (en) * | 2002-12-12 | 2003-01-15 | Novartis Nutrition Ag | New Compound |
CA2467695C (en) * | 2003-05-20 | 2010-03-16 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Isomaltooligosaccharides from leuconostoc as neutraceuticals |
ES2402687T3 (es) * | 2007-12-21 | 2013-05-07 | N.V. Nutricia | Uso de esfingomielina y carbohidratos no digeribles para mejorar la microbiota intestinal |
NZ595174A (en) * | 2009-03-13 | 2013-04-26 | Univ California | Prebiotic galacto oligosaccharides used to stimulate growth or colonisation of beneficial bifidobacterium bacteria in gut |
KR20140012045A (ko) | 2011-02-28 | 2014-01-29 | 미도리 리뉴어블즈 인코퍼레이티드 | 중합체 산 촉매 및 그의 사용 |
EP2888044A4 (en) | 2012-08-24 | 2016-05-04 | Midori Usa Inc | POLYMERIC AND SOLID-SUPPORTED CATALYSTS, AND METHODS OF DIGING CELLULOSIC MATERIALS USING SAID CATALYSTS |
CA2954662C (en) | 2014-07-09 | 2024-03-19 | Midori Usa, Inc. | Oligosaccharide compositions and methods for producing thereof |
-
2016
- 2016-04-23 US US15/568,251 patent/US20180296582A1/en not_active Abandoned
- 2016-04-23 SG SG11201708635QA patent/SG11201708635QA/en unknown
- 2016-04-23 EP EP16724150.4A patent/EP3285778A2/en active Pending
- 2016-04-23 CA CA2983016A patent/CA2983016A1/en not_active Abandoned
- 2016-04-23 JP JP2017555594A patent/JP2018513196A/ja active Pending
- 2016-04-23 RU RU2017134547A patent/RU2017134547A/ru not_active Application Discontinuation
- 2016-04-23 AU AU2016253011A patent/AU2016253011A1/en not_active Abandoned
- 2016-04-23 MX MX2017013562A patent/MX2017013562A/es unknown
- 2016-04-23 CN CN201680036013.1A patent/CN107708704A/zh active Pending
- 2016-04-23 WO PCT/US2016/029083 patent/WO2016172658A2/en active Application Filing
-
2019
- 2019-02-07 US US16/270,051 patent/US20200009168A1/en not_active Abandoned
-
2022
- 2022-01-19 US US17/579,067 patent/US20220395521A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
RU2017134547A (ru) | 2019-04-09 |
SG11201708635QA (en) | 2017-11-29 |
EP3285778A2 (en) | 2018-02-28 |
CA2983016A1 (en) | 2016-10-27 |
JP2018513196A (ja) | 2018-05-24 |
WO2016172658A3 (en) | 2016-12-01 |
US20220395521A1 (en) | 2022-12-15 |
US20200009168A1 (en) | 2020-01-09 |
WO2016172658A2 (en) | 2016-10-27 |
US20180296582A1 (en) | 2018-10-18 |
CN107708704A (zh) | 2018-02-16 |
AU2016253011A1 (en) | 2017-10-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2017013562A (es) | Reguladores de microbioma y usos relacionados de los mismos. | |
MX2021006581A (es) | Bacterias modificadas para tratar enfermedades asociadas con hiperamonemia. | |
PH12019500494A1 (en) | Formulations of (r)-2-amino-3-phenylpropyl carbamate | |
MX2019003623A (es) | Composiciones y metodos para el tratamiento de afecciones oftalmicas. | |
GEP20247593B (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
NZ724878A (en) | Compounds and compositions as toll-like receptor 7 agonists | |
MX2017006217A (es) | Polinucleotidos moduladores. | |
MX2021000848A (es) | Compuestos y sus usos para modular la hemoglobina. | |
PT3377637T (pt) | Composições para uso em métodos para o tratamento de ferimentos, transtornos e doenças da pele | |
GB2541571A (en) | Pharmaceutical compositions | |
EA201790273A1 (ru) | Флагеллиновые композиции и их применение | |
MX2015011769A (es) | Compuestos y sus usos para modular la hemoglobina. | |
MX2019000588A (es) | Moduladores de la somatostatina y usos de los mismos. | |
MX2015011509A (es) | Compuestos y usos de estos para la modulacion de la hemoglobina. | |
MX2015011445A (es) | Compuestos y usos de estos para la modulacion de la hemoglobina. | |
NZ720769A (en) | Anti-siglec-8 antibodies and methods of use thereof | |
PH12019502363A1 (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
PH12018501279A1 (en) | Compositions comprising 15-hepe and methods of using the same | |
MY180844A (en) | Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions | |
MX2017014456A (es) | Usos terapeuticos de l-4-cloroquinurenina. | |
MX2016008150A (es) | Formulaciones de berberina y usos de las mismas. | |
GB201213484D0 (en) | Pharmaceutical compositions comprising 15-OHEPA and methods of using the same | |
MX2018005987A (es) | Compuestos heterociclicos para el tratamiento de enfermedades. | |
WO2018045078A3 (en) | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING LYMPHATIC SYSTEM DISORDERS | |
MX2016002931A (es) | Moduladores del receptor x hepatico (lxr). |